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Abstract
Background: Tamoxifen has emerged as a potential management option for gynecomastia and breast pain due to
non-steroidal antiandrogens, and it is considered an alternative to surgery or radiotherapy. The objective of this
systematic review was to assess the benefits and harms of tamoxifen, in comparison to other treatment options,
for either the prophylaxis or treatment of breast events induced by non-steroidal antiandrogens in prostate cancer
patients.
Methods: We searched CENTRAL, MEDLINE, EMBASE, reference lists, the abstracts of three major conferences and
three trial registers to identify ongoing randomized controlled trials (RCTs). Two authors independently screened
the articles identified, assessed the trial quality and extracted data. The protocol was prospectively registered
(CRD42011001320; http://www.crd.york.ac.uk/PROSPERO).
Results: Four studies were identified. Tamoxifen significantly reduced the risk of suffering from gynecomastia (risk
ratio 9RR0 0.10, 95% CI 0.05 to 0.22) or breast pain (RR 0.06, 95% CI 0.02 to 0.17) at six months compared to
untreated controls. Tamoxifen also showed a significant benefit for the prevention of gynecomastia (RR 0.22,
95% CI 0.08 to 0.58) and breast pain (RR 0.25, 95% CI 0.10 to 0.64) when compared to anastrozole after a median
of 12 months. One study showed a significant benefit of tamoxifen for the prevention of gynecomastia (RR 0.24,
95% CI 0.09 to 0.65) and breast pain (RR 0.20, 95% CI 0.06 to 0.65) when compared with radiotherapy at six
months. Radiotherapy increased the risk of suffering from nipple erythema and skin irritation, but there were no
significant differences for any other adverse events (all P > 0.05).
Conclusions: The currently available evidence suggests good efficacy of tamoxifen for the prevention and
treatment of breast events induced by non-steroidal antiandrogens. The impact of tamoxifen therapy on long-term
adverse events, disease progression and survival remains unclear. Further large, well-designed RCTs, including long-
term follow-ups, are warranted. Also, the optimal dose needs to be clarified.
Keywords: Prostatic neoplasms, Androgen suppression therapy, Gynecomastia, Tamoxifen, Systematic review,
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Background
Prostate cancer growth is influenced by androgenic activity
[1], and androgen suppression therapy is a non-curative
therapeutic option for locally advanced, non-metastatic,
lymph-node positive, symptomatic or asymptomatic
metastatic prostate cancer either to slow progression or to
palliate symptoms of the disease [2]. Current guidelines
suggest surgical castration by bilateral orchiectomy and
monotherapy with luteinizing hormone-releasing hormone
(LHRH) agonists as the standard treatment for patients
with advanced prostate cancer. Antiandrogens are recom-
mended for short-term administration in patients receiv-
ing LHRH agonists and non-steroidal antiandrogen
monotherapy as an alternative to castration in patients
with locally advanced prostate cancer [2].
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Therapy with non-steroidal antiandrogens (admini-
strated either as monotherapy or in combination with
LHRH agonists) inhibits the effects of circulating testos-
terone at the androgen receptor level in prostate cells
[3,4]. The hormonal feedback mechanism increases the
secretion of luteinizing hormone from the pituitary
gland and consequently the secretion of testosterone
from the testes [3]. Non-suppressed testosterone levels
are important for sexual function. However, increased
levels of circulating testosterone also result in higher
estrogen levels because testosterone is peripherally aro-
matized to estrogen. This process stimulates the growth
of breast tissue, causing so-called breast events, such as
gynecomastia and breast pain [5]. In the Early Prostate
Cancer trial, gynecomastia and breast pain developed in
69% and 74% of 4,022 randomized patients, respectively,
treated with non-steroidal antiandrogens (bicalutamide
150 mg daily) within the first six to nine months, and
these adverse events were the major reasons for discon-
tinuation of therapy [6,7]. After diagnosis of gynecomas-
tia or breast pain the aim is to treat the symptoms and
to prevent further breast enlargement using radiotherapy
to the breast tissue, medical or surgical treatments.
However, it is unclear how many patients in this situa-
tion decide to undergo one of these therapy options.
Tamoxifen is an antiestrogen that has emerged as a
potential therapy for the management of gynecomastia
and breast pain [8-11]. Recent studies presented data
that tamoxifen might decrease the incidence of breast
events [12] and could lead to a complete resolution of
gynecomastia [13]. It is considered an alternative to sur-
gical treatment or radiotherapy to the breast tissue, and
its use has been discussed widely in the past [14-16].
However, no systematic reviews based on a comprehen-
sive literature search using predefined methodology
have yet evaluated the benefits and potential harms of
tamoxifen in comparison to other treatment options for
either the prophylaxis or treatment of breast events
induced by non-steroidal antiandrogens in prostate can-
cer patients.
Methods
The review protocol was prospectively registered in
the International Prospective Register of Systematic
Reviews (http://www.crd.york.ac.uk/PROSPERO;
CRD42011001320). We considered and searched (see
below) parallel group, randomized controlled trials
(RCTs) comparing tamoxifen with any other therapy
for the management of breast events induced by non-
steroidal antiandrogens in patients with prostate can-
cer. We imposed no limitations on the ethnicity of the
patients but excluded patients with neoplasms other
than prostate cancer or with breast events induced by
other diseases (such as, alcoholism). We evaluated the
effects of tamoxifen both in preventive and therapeutic
settings and assessed the following outcomes: gyneco-
mastia, breast pain, the incidence of adverse events
and discontinuation due to adverse events.
We initially searched the Cochrane Library (CEN-
TRAL, Issue 6), Ovid MEDLINE (1946 to June 2011)
and EMBASE (1947 to June 2011) electronically, and we
updated our search on April 7, 2012. The search strat-
egy was adapted for each electronic database [See Addi-
tional file 1, Table S1], and no language restrictions
were applied. We manually screened the reference lists
of all of the identified papers, and in June 2011 we
searched the abstracts of papers presented at the confer-
ences of (a) the American Society of Clinical Oncology
http://jco.ascopubs.org, (b) the European Association of
Urology http://www.uroweb.org and (c) the American
Urological Association http://www.abstracts2view.com/
aua/ and updated the search on April 7, 2012. In addi-
tion, we searched the following trial registers for
ongoing or completed studies: Current Controlled Trials
(http://www.controlled-trials.com, search updated on
April 7, 2012), ClinicalTrials.gov (http://www.clinical-
trials.gov, search updated on April 7, 2012), and the
search portal of the WHO (http://www.who.int/ictrp/en/
, search updated on April 7, 2012).
One author (FK) screened all of the identified refer-
ences, and only citations that were clearly irrelevant
were excluded at this stage. Two review authors (FK,
BK) then examined the full-text reports, identified
potentially relevant studies, assessed the eligibility of
studies for inclusion, extracted relevant data and
assessed the risk of bias of each study. We resolved any
disagreement on the eligibility of studies through dou-
ble-checking the respective reports, discussion between
the two authors and, if necessary, the help of a third
party (JM).
We used RevMan version 5.1, which was provided by
the Cochrane Collaboration http://www.cochrane.org,
for the statistical analysis of the data and calculated risk
ratios (RRs) with their 95% CIs for the chosen out-
comes. We assessed statistical heterogeneity (Chi2, I2)
and used a fixed-effect-model for I2 < 50% and in addi-
tion, a random-effects-model as sensitivity analysis if
I2 > 50%. All of the statistical tests were two-sided, and
P < 0.05 was considered statistically significant.
Results
A total of four studies published in 10 reports fulfilled
our inclusion criteria for this review. These studies were
published by Boccardo et al. [8,17-19] (Boccardo 2005),
Fradet et al. [12,20] (Fradet 2007), Perdona et al. [9,21]
(Perdona 2005), and Saltzstein et al. [13,22] (Saltzstein
2005). For the details of the search results, see Figure 1,
Table 1 and Table 2. We identified no ongoing studies
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and no studies that compared tamoxifen with surgical
therapies. We identified no additional study with our
updated search.
All of the included studies were multicenter trials. The
number of centers ranged from 5 (Perdona 2005) to 27
(Fradet 2007); the centers were located in either Europe
(Boccardo 2005, Fradet 2007, Perdona 2005) or North
America (Saltzstein 2005, Fradet 2007). Information on
the study populations was provided for all of the trials.
The trials included patients with localized or locally
advanced prostate cancer treated by local therapy (Fradet
2007, Perdona 2005, Saltzstein 2005), patients who were
not suitable for local therapy or patients who had refused
such treatments (Bedognetti 2010, Boccardo 2005). One
study also included patients presenting with recurrent dis-
ease after primary therapy (Boccardo 2005). However,
none of the studies included patients with metastatic dis-
ease. All of the patients were treated with bicalutamide
150 mg daily as the androgen-suppression therapy.
Reporting on detailed characteristics of the study metho-
dology was limited for all of the studies. In one study
(Boccardo 2005), patient recruitment was stopped after
interim analysis because of a higher incidence of breast
events in the control groups. For details on study
Figure 1 Search flow chart (June 2011).
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characteristics and risk of bias, see Table 1. We minimized
the impact of possible publication bias in conducting elec-
tronic and manual searches of multiple databases without
language restriction but were not able to perform a test
for funnel plot asymmetry because we did not identify at
least 10 studies.
Prevention of breast events
All four studies (Fradet 2007, Perdona 2005, Boccardo
2005, and Saltzstein 2005) provided data on the prevention
of gynecomastia and on breast pain for tamoxifen (10 mg
or 20 mg daily) compared to no additional therapy or to
placebo. Tamoxifen significantly reduced the risk of suffer-
ing from gynecomastia at 3 (RR 0.06, 95% CI 0.01 to 0.43),
6 (RR 0.10, 95% CI 0.05 to 0.22) and 9 to 12 (RR 0.17, 95%
CI 0.09 to 0.31) months compared to untreated controls
(Table 3). Tamoxifen also significantly reduced the risk of
enduring breast pain at 3 (RR 0.09, 95% CI 0.03 to 0.24), 6
(RR 0.06, 95% CI 0.02 to 0.17) and 9 to 12 (RR 0.13, 95%
CI 0.06 to .27) months compared to untreated controls
Table 1 Study characteristics.
Boccardo 2005 Fradet 2007 Perdona 2005 Saltzstein 2005
Design RCT, three arms RCT, six armsb RCT, three arms RCT, three arms
Intervention tamoxifen 20 mg/d (37
patients)
tamoxifen 20 mg/d (35
patients)
tamoxifen 10 mg/d (50
patients)
tamoxifen 20 mg/d (35
patients)
Control - anastrozole 1 mg/d
(36 patients);
- placebo (60 patients)b - radiotherapy (single
fraction of 12 Gy, (50
patients);
- anastrozole 1 mg/d (36
patients);
- placebo (40 patients) - no additional therapy
(51 patients)
- placebo (36 patients)
Assessment of
gynecomastia
by breast ultrasound or
caliper. ("Severity was scored
on the basis of the largest
diameter as follows: grade 1,
≤ 2 cm; grade 2, more than 2
to ≤ 4 cm; grade 3, more
than 4 to ≤ 6 cm; and grade
4, more than 6 cm.”)
by patient questioning and
calipers ("recorded in
centimeters to the nearest
0.5 cm”)
by calipers ("Severity was
scored on the basis of the
largest diameter: grade 1 (≤ 2
cm); grade 2 (from 2 to ≤ 4
cm); grade 3 (from 4 cm to ≤
6 cm); and grade 4 (> 6 cm))”
by physical examination and
direct patient questioning
("Criteria for a response to






by direct patient questioning
at each visit ("scored
according to severity as none,
mild to moderate, or severe”)a
by direct patient
questioning ("rated as mild





normal activities), or severe
(incapacitating resulting in
an inability to perform
normal activities”)
by direct patient questioning
at each visit ("scored as none,
mild, moderate, or severe”)
by direct patient questioning
("Criteria for a response to













were not reused, schedule
prepared at each center
Allocation
concealment



















low risk of biasc low risk of biasc low risk of biasc low risk of biasc
Selective reporting low risk of biasd low risk of biasd low risk of biasd low risk of biasd
Other remarks recruitment was stopped
early because of planned
interim analysis, research
funding by AstraZeneca (no
role in study design, analysis
or interpretation of data)
co-author is an employee of
AstraZeneca, writing support
funded by AstraZeneca
authors declared no conflict
of interest
co-authors are employees of
AstraZeneca, no conflict of
interest mentioned in
manuscript
aWe included the following pain degrees: mild to moderate, severe; bThis study compared multiple dosages of tamoxifen (1, 2.5, 5, 10, or 20 mg daily) with
placebo. In this review, we included only the groups treated with tamoxifen 20 mg compared with placebo; cWe found no evidence for missing outcome data.
Additionally, outcome data were presented by intention-to-treat; dThe study protocol is not available, but we assume that the published reports include all
evaluated outcomes. RCT, randomized controlled trial.
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(Table 3). Additionally, a sensitivity analysis using a ran-
dom-effects model for the prevention of breast pain at
three months revealed (I2 74%) significant results favoring
tamoxifen compared to untreated controls (RR 0.10, 95%
CI 0.01 to 0.90).
Two studies (Boccardo 2005 and Saltzstein 2005)
reported data on the prevention of gynecomastia or
breast pain with tamoxifen (20 mg daily) versus the aro-
matase inhibitor anastrozole (1 mg daily, see Table 3).
One study (Boccardo 2005) showed a significant benefit
of tamoxifen in the prevention of gynecomastia after a
median of 12 months (RR 0.22, 95% CI 0.08 to 0.58),
and two studies (Boccardo 2005 and Saltzstein 2005)
provided data on the prevention of breast pain, demon-
strating a statistically significant difference favoring
tamoxifen after a median of 12 months (RR 0.25, 95%
CI 0.1 to 0.64).
One study (Perdona 2005) reported data on the preven-
tion of gynecomastia or breast pain with tamoxifen (10 mg
daily) versus radiotherapy (single fraction of 12 Gy), show-
ing significant benefit of tamoxifen for the prevention of
gynecomastia (RR 0.24, 95% CI 0.09 to 0.65) and for the
prevention of breast pain at six months, respectively (RR
0.2, 95% CI 0.06 to 0.65, Table 3).
Treatment of breast events
One study (Saltzstein 2005) showed a significant difference
favoring tamoxifen for the treatment of breast events
(including gynecomastia/breast pain) at three months (RR
0.38, 95% CI 0.25 to 0.58, Table 4), and Perdona et al.
(Perdona 2005) reported that tamoxifen significantly
improved the symptoms of gynecomastia, breast pain or
both compared with radiotherapy at nine months (RR
0.21, 95% CI 0.05 to 0.83, Table 4). Perdona et al. pre-
sented data for patients with grade 3-4 gynecomastia
(> 4 cm) who experienced a change of disease to grade 1-2
gynecomastia (≤ 4 cm) [9] and Saltzstein et al. reported
data for the time to resolution of breast events [13].
Tolerability of tamoxifen
Two studies (Fradet 2007 and Saltzstein 2005) reported
data on discontinuation due to adverse events. However,
only Saltzstein et al. specified the adverse events that
led to discontinuation (gynecomastia: two; breast pain:
five; moderate rise of liver enzymes: one). [13] There
Table 2 Excluded studies with reasons for exclusion.
Authors Reason for exclusion
Bedognetti et al. [23,24] Study did not evaluate our predefined
comparisona
Boccardo et al. [37] No relevant topicb
Eaton et al. [25] Only abstract available and data not
sufficiently detailed to include in reviewc
Parker et al. [11] No prostate cancer patients
Serretta et al. [38,39] Study did not evaluate our predefined
comparisond
aTamoxifen 20 mg daily versus tamoxifen 20 mg once weekly; bEvaluation of
insulin-like growth factor 1 and binding proteins in prostate cancer;
cTamoxifen 20 mg once weekly versus no additional therapy; dTamoxifen 20
mg/daily given at the early onset of gynecomastia (within one month) for a
period of one year versus Tamoxifen 10 mg/daily given for one year starting
at the bicalutamide prescription.
Table 3 Prevention of breast events.
Outcome Studies Participants Risk Ratio (M-H, Fixed, 95% CI), I2
Tamoxifen (10 or 20 mg daily) versus no therapy/placebo
Prevention of gynecomastia
• at 3 months Fradet 2007 94 0.06 (0.01, 0.43), -
• at 6 months Fradet 2007, Perdona 2005 195 0.10 (0.05, 0.22), 0%
• at 9 to 12 months Boccardo 2005, Fradet 2007 171 0.17 (0.09, 0.31), 0%
Prevention of breast pain
• at 3 months Fradet 2007, Saltzstein 2005 165 0.09 (0.03, 0.24), 74%a
• at 6 months Fradet 2006, Perdona 2005 195 0.06 (0.02, 0.17), 27%
• at 9 to 12 months Boccardo 2005, Fradet 2007 171 0.13 (0.06, 0.27), 0%
Tamoxifen (20 mg daily) versus anastrozole (1 mg daily)
Prevention of gynecomastia
• median 12 months Boccardo 2005 73 0.22 (0.08, 0.58), -
Prevention of breast pain
• median 12 months Boccardo 2005, Saltzstein 2005 143 0.25 (0.10, 0.64), 0%
Tamoxifen (10 mg daily) versus radiotherapy
Prevention of gynecomastia
• at 6 months Perdona 2005 100 0.24 (0.09, 0.65), -
Prevention of breast pain
• at 6 months Perdona 2005 100 0.20 (0.06, 0.65), -
aRisk ratio with random effects model (M-H, 95% CI) 0.10 (0.01 to 0.90).
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were no significant differences between tamoxifen 20
mg daily and placebo (RR 0.92, 95% CI 0.38 to 2.23,
Additional file 1, Table S2) or between tamoxifen 20 mg
daily and anastrozole 1 mg daily with regard to disconti-
nuations (RR 0.86, 95% CI 0.29 to 2.55, Additional
file 1, Table S3). This was, however, probably due to
low numbers of discontinuations.
All of the included studies (Boccardo 2005, Saltzstein
2005, Perdona 2005 and Fradet 2007) presented data on
adverse events for tamoxifen (10 mg or 20 mg daily) ver-
sus no additional therapy or placebo. There were no sig-
nificant differences for any adverse events [See Additional
file 1, Table S2, all P > 0.05]. Two studies (Boccardo 2005
and Saltzstein 2005) reported data on adverse events for
tamoxifen (20 mg daily) compared to anastrozole (1 mg
daily, Additional file 1, Table S3). In total, fewer adverse
events occurred with tamoxifen (RR 0.51, 95% CI 0.31 to
0.82), but there were no significant differences for indivi-
dual adverse events [See Additional file 1, Table S3, all P >
0.05]. A single fraction of 12 Gy, compared to tamoxifen
10 mg daily, significantly increased the risk of suffering
from nipple erythema (RR 0.11, 95% CI 0.03 to 0.43) and
from skin irritation (RR 0.03, 95% CI 0.00 to 0.41) but not
the risk for other adverse events [See Additional file 1,
Table S4, all P > 0.05]. The authors noted that all radio-
therapy-associated adverse events resolved and were of
short duration (median 4 weeks; Perdona 2005).
Discussion
We evaluated the efficacy of tamoxifen for the manage-
ment of breast events induced by non-steroidal antiandro-
gens in patients with prostate cancer. Our findings suggest
that tamoxifen is more effective for both the prevention
and treatment of gynecomastia and breast pain compared
to other therapies, such as radiotherapy or the selective
aromatase inhibitor anastrozole.
We included data from studies evaluating tamoxifen
compared to any other therapy for the management of
breast events. The criteria for diagnosis of gynecomastia,
however, varied among the included studies. The assess-
ment was performed by either examination or patient
questioning. This discrepancy could have led to different
incidences of breast events in the studies. Additionally,
the grading of the severity of breast pain was different in
the included studies and ranged from no pain to severe
pain. However, breast pain was assessed in all of the stu-
dies by direct patient questioning, and even if the severity
of breast events is reported to be moderate, this disease is
often a reason for patients withdrawing from therapy.
We included tamoxifen with dosages of 10 mg or 20 mg
daily in the meta-analysis because Fradet et al. found no
significant differences in their dose-response study when
tamoxifen 20 mg daily was compared to 10 mg daily [12].
However, we included only studies using tamoxifen con-
tinuously without interruption. Therapy with tamoxifen is
likely to be most effective if it is administered continu-
ously. Bedognetti et al. demonstrated that the beneficial
effects of tamoxifen 20 mg daily after eight weeks for the
prevention of gynecomastia were only significant when
administering the drug continuously as opposed to weekly
[23,24]. However, there is also evidence that tamoxifen
20 mg once weekly might be superior to no additional
therapy [25]. Conversely, Fradet et al. noted that in all of
the groups (irrespective of dose), a high incidence (> 90%)
of breast events occurred after stopping tamoxifen therapy
[12,20].
Our results suggest that tamoxifen has a beneficial effect
if compared to no treatment for the prevention of breast
events. However, not all patients need prophylaxis to pre-
vent the development of breast events induced by non-
steroidal antiandrogen therapy [26,27], and not all patients
with gynecomastia require treatment [28]. Therefore, a
patient-oriented, pragmatic approach appears reasonable.
This approach was also proposed by van Poppel and by Di
Lorenzo et al. [14,15,27]. Before starting non-steroidal
antiandrogen treatment (either with non-steroidal mono-
therapy or in combination with LHRH analogues), patients
should be informed about the likelihood of breast events
and about possible prophylactic therapy options. As
recommended earlier by Di Lorenzo et al. [14,15], we also
suggest that the physician could wait for the occurrence of
breast events in selected patients. Prophylaxis should be
started only if the patient is afraid of developing gyneco-
mastia or breast pain.
Our findings regarding the comparison of tamoxifen
versus radiotherapy show a beneficial effect favoring
tamoxifen for the prevention of breast events, but these
results are based on a single study. There is evidence,
Table 4 Treatment of breast events.
Outcome Studies Participants Risk Ratio (M-H, Fixed, 95% CI), I2
Tamoxifen (20 mg daily) versus anastrozole (1 mg daily)
Treatment of breast events
• at 3 months Saltzstein 2005 90 0.38 (0.25, 0.58), -
Tamoxifen (10 mg daily) versus radiotherapy
Treatment of gynecomastia/breast pain/or both
• after 9 months Perdona 2005 35 0.21 (0.05, 0.83), -
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however, that radiotherapy is also an effective treatment
option for breast events. A randomized trial compared a
single dose of radiotherapy (10 Gy) with sham radio-
therapy for the prevention of breast events and found a
significant difference favoring interventional treatment
(P < 0.001) [29]. Additionally, a non-randomized, com-
parative study of 253 patients participating in a Scandi-
navian trial demonstrated a decreased risk for the
development of gynecomastia and breast pain with
radiotherapy compared with no additional treatment
[30]. An expert recommended using radiotherapy as the
therapy of choice for the prevention of breast events
[27].
Most adverse events were rare in both groups and we
found no significant differences for any single adverse
event comparing tamoxifen with anastrozole [See Addi-
tional file 1, Table S3]. Only the risks for nipple erythema
and skin irritation were increased with radiotherapy
compared to tamoxifen. Several retrospective and non-
comparative studies have suggested that radiotherapy is an
option with few and mild acute side effects and with no
long-term adverse events [31-33]. The most common side
effect with radiotherapy was reversible skin erythema [34].
However, Nieder et al. provided data demonstrating that
exposing the heart to prophylactic radiotherapy of the
mammillary region might contribute to cardiac side effects
[35]. A narrative review evaluating safety and tolerability
did not conclude either these cardiac side effects or sec-
ondary malignancies or pulmonary events, but it noted
that no studies have evaluated the long-term effects of
radiotherapy in men [34].
We were not able to identify any studies that compared
tamoxifen with surgical therapies, such as subcutaneous
mastectomy and/or liposuction. Therefore, we cannot
draw any conclusions regarding this potential alternative
therapy option. Surgical therapies aim to reduce breast
size to a normal body contour and to eliminate painful tis-
sue [15,16,36]. Experts in the field of gynecomastia treat-
ment have suggested that surgical liposuction is a valuable
therapy option in very early stages and that it is a simple
and acceptable technique [15,16]. Other experts have only
considered surgical therapies in patients with reduced
quality of life due to breast events or to distinct or long-
standing gynecomastia [28,36]. This option appears rea-
sonable because gynecomastia presenting for longer than
12 months is unlikely to resolve due to irreversible
changes in the breast tissue [5,36]. However, surgical
therapies always have potential side effects, such as infec-
tions, necrosis, loss of sensation and postoperative body
deformity, and should therefore be reserved as a secondary
treatment for selected patients.
Our results show that the antiestrogen tamoxifen is a
useful therapeutic option for the prevention and treatment
of breast events. However, in addition to the discussion of
our results, it should be mentioned that treatment with
antiestrogens for hormone-dependent tumors, such as
prostate cancer, raises some concerns. On the one hand,
blocking the effect of estrogens results in effective preven-
tion of breast events induced by non-steroidal antiandro-
gens [14]. On the other hand, this hormonal manipulation
could increase androgen secretion by blocking the negative
feedback control of estrogens [14]. Although several trials
have investigated the potential effects of tamoxifen co-
administration on prostate-specific antigen (PSA) inhibi-
tion and on the levels of sex hormones [8,12,13,18,23-25],
none of them presented long-term follow-up data. There-
fore, the impact of tamoxifen therapy on outcomes, such
as long-term adverse events, progression and survival,
remains unclear and should be considered when prescrib-
ing this treatment.
We did not identify any studies with long-term follow-
ups, and evidence for treatment with tamoxifen is lim-
ited because there are only a few studies with few
events. Despite its potential limitations, this systematic
review provides evidence-based guidance to clinicians
on this clinically relevant topic. It demonstrates good
efficacy of tamoxifen for the prevention and treatment
of breast events induced by non-steroidal antiandrogens.
This important question, however, requires more defini-
tive answers, and further research with high-quality
RCTs and longer-term follow-up is warranted.
Conclusions
The currently available evidence shows good efficacy of
tamoxifen for either the prophylaxis or treatment of
breast events induced by non-steroidal antiandrogens in
prostate cancer patients. It should be taken into account
that evidence is limited because there are only a small
number of studies with few events and only short-term
follow-up. Therefore, the impact of tamoxifen therapy
on long-term adverse events, disease progression and
survival remains unclear. Further research with high-
quality RCTs and longer-term follow-up is warranted to
investigate the benefits and harms of tamoxifen 10 mg
and 20 mg compared with radiotherapy.
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events: Tamoxifen (10 or 20 mg daily) versus no additional therapy
or placebo Table S3: Adverse events: Tamoxifen (20 mg daily)
versus anastrozole (1 mg daily) Table S4: Adverse events:
Tamoxifen (10 mg daily) versus radiotherapy (single fraction of 12
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